For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com  Inclusion Criteria:  Must have sufficient command of the Japanese language to understand the study instructions and requirements Must be a resident of Japan  Must have received prior treatment with:  a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody Subjects must be either 2-4 months, 5-7 months, or 8-11 months post triple class therapy exposure at time of consent Subject must be diagnosed with multiple myeloma  Exclusion Criteria:  Participants enrolled in a clinical trial that includes at least one novel/ experimental agent at the point of questionnaire completion  Other protocol-defined inclusion/exclusion criteria apply.